Overcoming resistance to targeted anticancer drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
   Article
2. Enzyme-instructed self-assembly: a multistep process for potential cancer therapy.Bioconjugate chemistry · 2015
   Review
3. Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.Experimental and therapeutic medicine · 2015
   Article
4. Translational research in oncology--10 years of progress and future prospects.Nature reviews. Clinical oncology · 2014
   Review

Corrections and comments

• Comment on
  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.2013

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as